CasInvent Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CasInvent Pharma is a private, preclinical-stage biotech leveraging a proprietary platform of best-in-class CK1 kinase inhibitors to address therapy-resistant cancers. Founded as a university spin-off with backing from i&i Prague, the company is advancing a lead candidate towards clinical trials for AML and solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC). The leadership team combines deep drug discovery expertise from Big Pharma with strong academic roots in CK1 biology and chemistry, positioning the company to potentially unlock a novel oncology target.

Oncology

Technology Platform

Proprietary platform for discovering highly potent and selective small molecule inhibitors of Casein Kinase 1 (CK1) isoforms, based on integrated expertise in CK1 biology and kinase inhibitor chemistry.

Opportunities

The company is targeting a major unmet need in oncology—therapy-resistant tumors—with a first-in-class mechanism targeting CK1 kinases.

Success could lead to treatments for aggressive cancers like AML and PDAC with poor prognoses.

The platform also offers potential for expansion into other disease areas linked to CK1 dysregulation.

Risk Factors

Key risks include the preclinical nature of the asset with unproven clinical efficacy/safety, dependence on securing significant future financing to reach clinical trials, and the inherent challenges of being a novel, single-asset company in a competitive oncology field.

Competitive Landscape

The competitive landscape for selective CK1 inhibitors in oncology is relatively sparse, positioning CasInvent as a potential pioneer. However, they may face future competition from larger biopharma and other biotechs entering the space. Their success will depend on achieving clinical proof-of-concept ahead of potential rivals.

More companies in Small Molecule Drugs →More companies in Czech Republic →